Content about Pfizer

July 8, 2013

Consumers have access to more information than ever before, and that creates a new challenge for brands today, Thomas “TJ” Higgins, president, U.S., Pfizer Consumer Healthcare told DSNtv in a special edition of DSN Executive Viewpoints. “The pressure is on our brand teams today to get more information [to the consumer]. We have to get more specific; more personalized."

Consumers have access to more information than ever before, and that creates a new challenge for brands today, Thomas “TJ” Higgins, president, U.S. of Pfizer Consumer Healthcare told DSNTV in a special edition of DSN Executive Viewpoints. “The pressure is on our brand teams today to get more information [to the consumer]. We have to get more specific, more personalized,” Higgins said. “As the consumer has access to more information, they want to know not what’s good for the general population, but what’s good for me?

February 1, 2012

As part of DSN's Executive Retailer Viewpoint series, DSN sat down with Jason Reiser, VP health and wellness, ops/compliance at Sam's Club, at DSN's Industry Issues Summit to discuss how to better engage customers and the impact of the economy on business in 2012.

As part of DSN's Executive Retailer Viewpoint series, DSN sat down with Jason Reiser, VP health and wellness, ops/compliance at Sam's Club, at DSN's Industry Issues Summit to discuss how to better engage customers and the impact of the economy on business in 2012.

January 18, 2012

In an effort to tap into the minds of some of the industry's top executives, Drug Store News recently sat down and talked with some of these leaders in a multipart executive viewpoint video series.

In an effort to tap into the minds of some of the industry's top executives, Drug Store News recently sat down and talked with some of these leaders in a multipart executive viewpoint video series.

This powerful series, sponsored by Pfizer, is comprised of five different on-camera executive interviews that are a must see for anyone working within the retail pharmacy industry.

April 21, 2014

Pfizer recently launched Robitussin Maximum Strength Cough + Congestion DM, a new liquid-filled capsule that helps control cough on the go.

MADISON, N.J. — Pfizer recently launched Robitussin Maximum Strength Cough + Congestion DM, a new liquid-filled capsule that helps control cough on the go. The new capsule formulation contains 10 mg of dextromethorphan as a cough suppressant and 200 mg of guaifenesin as an expectorant. For adults and children older than 12 years, the new formulation will help temporarily relieve cough due to minor throat and bronchial irritation, and help loosen phlegm and thin bronchial secretions to drain bronchial tubes.

April 21, 2014

Pfizer is making a bid of $100.8 billion (£60 billion) for Astra Zeneca, according to a report in the Sunday Times, published Sunday.

LONDON — Pfizer is making a bid of $100.8 billion (£60 billion) for Astra Zeneca, according to a report in the Sunday Times, a U.K. daily, published Sunday. 

Citing insiders, the Sunday Times reported that, internally, Astra Zeneca is resisting the overture. 

"The New York company is keen to deploy a $70 billion (£42 billion) cash pile that it has accumulated in overseas subsidiaries," the paper reported.

April 17, 2014

Teva Pharmaceutical announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

JERUSALEM — Teva Pharmaceutical on Thursday announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100-, 200- and 400-mg capsules. 

April 15, 2014

Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products.

PEAPACK, N.J. — Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products. The drug is the authorized generic versions of Caduet.

April 14, 2014

Pfizer Consumer Healthcare on Monday teamed up with actor and active volunteer Josh Duhamel for the Advil Relief in Action campaign, which features the #ReliefinAction Pledge on Facebook and a Mobile Relief Center tour making approximately 100 stops throughout the country.

MADISON, N.J. — Pfizer Consumer Healthcare on Monday teamed up with actor and active volunteer Josh Duhamel for the Advil Relief in Action campaign, which features the #ReliefinAction Pledge on Facebook and a Mobile Relief Center tour making approximately 100 stops throughout the country.

April 11, 2014

Ian Read, chairman and CEO of Pfizer, was elected chairman of the Pharmaceutical Research and Manufacturers of America at the trade association’s annual meeting.

WASHINGTON — Ian Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America Friday at the trade association’s annual meeting. Also elected were Kenneth Frazier, chairman, president and CEO of Merck, as chairman-elect of the PhRMA board of directors, and George Scangos, CEO of Biogen Idec, as board treasurer.

Read succeeds Robert Hugin, chairman and CEO of Celgene Corp., as PhRMA’s chairman.

March 31, 2014

The Food and Drug Administration on Friday approved over-the-counter Nexium 24HR (esomeprazole 20mg), Pfizer announced.

NEW YORK — The Food and Drug Administration on Friday approved over-the-counter Nexium 24HR (esomeprazole 20mg), Pfizer announced. 

“Switching medicines, whenever appropriate, from prescription to non-prescription status improves access, empowers consumers to care for their own health and is an important strategy for Pfizer,” stated Paul Sturman, president, Pfizer Consumer Healthcare. “The FDA approval of Nexium 24HR is a significant milestone in executing against our plan.”

March 31, 2014

Greenstone announced the introduction of Piroxicam capsules to its generic pharmaceutical product line. The drug is offered in dosage strengths of 10 mg and 20 mg, and is the generic equivalent to Feldene.

PEAPACK, N.J. — Greenstone announced the introduction of Piroxicam capsules to its generic pharmaceutical product line. The drug is offered in dosage strengths of 10 mg and 20 mg, and is the generic equivalent to Feldene.

Piroxicam is intended for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. This new, authorized generic adds to Greenstone’s growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., the company said.

 

March 28, 2014

Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

HYDERABAD, India — Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

The Caduet tablets brand and generic had sales in the United States of approximately $163 million MAT for the most recent 12 months ended January 2014, according to IMS Health.

March 26, 2014

Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel. The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina.

DUBLIN and LAVAL, Quebec — Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel.

The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina. It's the most common vaginal infection in women ages 15 years to 44 years. Metronidazole 1.3% provides a single-dose treatment that is packaged in a pre-filled disposable applicator.

March 21, 2014

New guidelines for using statins to treat high cholesterol and prevent cardiovascular disease are projected to result in 12.8 million more U.S. adults taking the drugs, according to a research team led by Duke Medicine scientists.

DURHAM, N.C. — New guidelines for using statins to treat high cholesterol and prevent cardiovascular disease are projected to result in 12.8 million more U.S. adults taking the drugs, according to a research team led by Duke Medicine scientists. Overall, of the 12.8 million additional U.S. adults recommended for statin use under the new guidelines, 10.4 million are people who would be prescribed the drugs for preventive care. Of those preventive users, 8.3 million would be people over the age of 60. 

March 20, 2014

Members of the board of directors of the Consumer Healthcare Products Association on Wednesday were elected at the association’s Annual Executive Conference at Amelia Island, Fla.

AMELIA ISLAND, Fla. — Members of the board of directors of the Consumer Healthcare Products Association on Wednesday were elected at the association’s Annual Executive Conference. James Mackey, SVP U.S. Region Head, Merck Consumer Care, will continue to serve as chair for a second term.  

March 18, 2014

Pfizer has sued Torrent Pharmaceuticals in an effort to protect its erectile-dysfunction drug Viagra (sildenafil citrate) from generic competition, according to a Bloomberg News report published Tuesday.

NEW YORK — Pfizer has sued Torrent Pharmaceuticals in an effort to protect its erectile-dysfunction drug Viagra (sildenafil citrate) from generic competition, according to a Bloomberg News report published Tuesday

Torrent has filed an aNDA with the Food and Drug Administration, challenging Pfizer's patent that expires on Oct. 22, 2019. 

March 17, 2014

Bristol-Myers Squibb Co. and Pfizer announced that the Food and Drug Administration approved a supplemental new drug application for Eliquis (apixaban). The drug is a preventive treatment for deep vein thrombosis, which can lead to pulmonary embolism for patients who have had hip or knee replacement surgery.

PRINCETON, N.J. and NEW YORK — Bristol-Myers Squibb Co. and Pfizer announced that the Food and Drug Administration approved a supplemental new drug application for Eliquis (apixaban). The drug is a preventive treatment for deep vein thrombosis, which can lead to pulmonary embolism for patients who have had hip or knee replacement surgery.  

March 13, 2014

More Americans are more often seeking their ounce of prevention. According to Bain & Co.’s recent Healthy Living Survey, 75% of consumers are in pursuit of a healthier lifestyle. Take that predominant mindset, coupled with the outcomes-driven preventive focus associated with the Affordable Care Act, and you have a formula for OTC success at retail pharmacy.

More Americans are more often seeking their ounce of prevention. According to Bain & Co.’s recent Healthy Living Survey, 75% of consumers are in pursuit of a healthier lifestyle. Take that predominant mindset, coupled with the outcomes-driven preventive focus associated with the Affordable Care Act, and you have a formula for OTC success at retail pharmacy.

To get a better sense of how OTC brands are helping to improve patient outcomes and drive down healthcare costs, DSN invited some leading OTC executives to share their opinions on the value of OTCs.

March 10, 2014

Two Rx-to-OTC switches in the past year may serve as a harbinger of what the Food and Drug Administration will consider “switch” worthy.

Two Rx-to-OTC switches in the past year may serve as a harbinger of what the Food and Drug Administration will consider “switch” worthy. They both address chronic care needs, and they both represent first of their kind medicines to the nonprescription aisle.

March 7, 2014

It's finally happening. Pfizer has placed the ball at the line of scrimmage. And based on the X's and O's to come out of its Lipitor OTC actual-use study, Pfizer will be making its run with its eye on the ultimate prize — a successful Rx-to-OTC switch of a statin.

Only this time, the Food and Drug Administration may not be as quick to sack Pfizer's switch attempt. With the advances and pervasion of health technology in the self-care space by way of smartphones and tablets; with the evolution of the pharmacist as a healthcare professional able to practice at the top of their license; and with the adoption of diagnostic tests like a cholesterol panel that can be physically administered in the pharmacy, consumers may finally get it right when self-selecting a statin.

Because it's the consumer actual-use studies that have scuttled just about every statin switch attempt in the past. In the last switch of Mevacor, FDA advisory panelists determined the statin was safe enough for the self-care space. And it was effective. It's just that the consumers who would be right for an OTC statin didn't appropriately self-select. And if they can't appropriately self-select, what's the point, really?

It's finally happening. Pfizer has placed the ball at the line of scrimmage. And based on the X's and O's to come out of its Lipitor OTC actual-use study, Pfizer will be making its run with its eye on the ultimate prize — a successful Rx-to-OTC switch of a statin. 

March 3, 2014

An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday.

CAMBRIDGE, Mass. — An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday. The results focus the search for developing novel therapeutic strategies for Type 2 diabetes — if a drug can be developed that mimics the protective effect of these mutations, it could open up new ways of preventing this devastating disease.

March 3, 2014

Pfizer is recruiting for a 1,200-patient actual use study to measure whether or not patients can appropriately self-select treating high cholesterol with the statin Lipitor, the Wall Street Journal reported on Sunday.

NEW YORK — Pfizer is recruiting for a 1,200-patient actual use study to measure whether or not patients can appropriately self-select treating high cholesterol with the statin Lipitor, the Wall Street Journal reported on Sunday. 

The trial is recruiting patients through more than 35 pharmacies and is expected to be completed by year-end.  

February 28, 2014

Lupin announced that it received approval from the Food and Drug Administration for rifabutin capsules USP, 150-mg, a generic version of Pharmacia and Upjohn Company's Mycobutin capsules.

MUMBAI and BALTIMORE — Lupin on Wednesday announced that it received approval from the Food and Drug Administration for rifabutin capsules USP, 150 mg — a generic version of Pharmacia and Upjohn Company's Mycobutin capsules. The company's U.S. subsidiary will begin marketing the product soon.

The drug is used for the prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection. Mycobutin capsules had annual sales of $18.6 million in the United States, according to IMS MAT.

 

January 23, 2014

Match.com and Pfizer announced results from a recent survey showing that single smokers may want to consider breaking up with their cigarettes as they look for that special someone this year.

NEW YORK — Match.com and Pfizer on Wednesday announced results from a recent survey showing that single smokers may want to consider breaking up with their cigarettes as they look for that special someone this year. Nearly 9-in-10 (89%) respondents said they prefer not to date someone who smokes, and when asked which actions were unacceptable on a first date, more said taking a smoke break (51%) than checking one’s phone (45%) or being late (40%).

January 21, 2014

Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line.

PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100. 

Greenstone’s Sirolimus product is the authorized generic of, and equivalent to, Pfizer's Rapamune (sirolimus).